Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $16.88.

A number of brokerages have recently issued reports on FOLD. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Cantor Fitzgerald lifted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Guggenheim increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $10,161,054.84. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 30,401 shares of company stock worth $339,363 in the last 90 days. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of Amicus Therapeutics

Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after buying an additional 2,856,101 shares during the last quarter. William Blair Investment Management LLC boosted its position in Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after purchasing an additional 1,477,084 shares in the last quarter. Geode Capital Management LLC grew its stake in Amicus Therapeutics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after acquiring an additional 80,926 shares during the period. Fiera Capital Corp grew its position in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after purchasing an additional 58,113 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its stake in Amicus Therapeutics by 4.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock worth $33,749,000 after buying an additional 139,491 shares in the last quarter.

Amicus Therapeutics Trading Up 0.7 %

Shares of NASDAQ:FOLD opened at $9.80 on Friday. The stock’s 50-day simple moving average is $10.49 and its two-hundred day simple moving average is $10.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of -28.82 and a beta of 0.60. Amicus Therapeutics has a 52-week low of $9.02 and a 52-week high of $14.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.